Abstract:Bladder cancer (BC) is one of the most prevalent malignancies globally. Despite recent advancements, resistance to conventional treatments such as surgery, chemotherapy, and immunotherapy remains common among BC patients. Thus, developing novel therapeutic agents or enhancing the efficacy of current treatments is essential for better management of BC. Oncolytic adenoviruses represent a promising new approach, capable of inflaming the tumor microenvironment and eliciting tumor-specific T cell responses. In this study, we aimed to understand the immune mechanisms involved in the antitumor therapeutic efficacy of oAd/IL-12/shVEGF—an oncolytic adenovirus co-expressing interleukin-12 (IL-12) and short hairpin RNA targeting vascular endothelial growth factor (shVEGF)—both in vitro and in vivo against BC. To investigate the therapeutic potential of oAd/IL-12/shVEGF in a syngeneic MB49 BC model, tumor-bearing mice were intratumorally injected with the oncolytic virus when tumors reached 70-100 mm3. Tumor volume and body weight were monitored until the end of the experiment. Mice were sacrificed when tumors reached 2000 mm3, and both tumor and spleen tissues were disaggregated for analysis. Tumor tissues were examined for proliferation marker (PCNA), adenovirus injection marker (E1A), and antitumor immune marker (CD8) using H&E and immunohistochemical analysis. To evaluate immune modulation, levels of IFN-γ, TNF-α, and IL-12 in tumor tissues and splenocytes were measured using ELISA kits. Tumor-specific immune responses were assessed by evaluating the number of IFN-γ-secreting immune cells in splenocytes via ELISPOT assay. Statistical analysis was performed using one-way ANOVA. Treatment with oAd/IL-12/shVEGF significantly suppressed tumor growth compared to PBS-treated controls. The oncolytic virus increased levels of IFN-γ, TNF-α, and IL-12 in both tumor tissues and splenocytes compared to PBS. Additionally, oAd/IL-12/shVEGF enhanced CD8+ T cell infiltration into tumor tissues and significantly reduced PCNA expression, indicating decreased tumor cell proliferation. Consistent with these findings, the number of IFN-γ-secreting immune cells was significantly higher in mice treated with oAd/IL-12/shVEGF compared to those treated with PBS. These results suggest that oAd/IL-12/shVEGF is a promising clinical cancer immunotherapeutic agent for inducing antitumor immunity in bladder cancer. Citation Format: Yunlim Kim, Bum Jin Lim, A-Rum Yoon, Chae-Ok Yun, Choung-Soo Kim. Oncolytic adenovirus induces potent anti-tumor efficacy via robust activation of immune cells in bladder cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr A058.

Oncolytic Adenoviral Vector-Mediated Expression of an Anti-PD-L1-scFv Improves Anti-Tumoral Efficacy in a Melanoma Mouse Model

A dual-functional oncolytic adenovirus ZD55-aPD-L1 scFv armed with PD-L1 inhibitor potentiates its antitumor activity

Adenovirus-Mediated Inducible Expression of a PD-L1 Blocking Antibody in Combination with Macrophage Depletion Improves Survival in a Mouse Model of Peritoneal Carcinomatosis

Controlled release of enhanced cross-hybrid IgGA Fc PD-L1 inhibitors using oncolytic adenoviruses

Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model

RCAd-LTH-shPD-L1, a double-gene recombinant oncolytic adenovirus with enhanced antitumor immunity, increases lymphocyte infiltration and reshapes the tumor microenvironment

Abstract B054: Enhanced Antitumor Efficacy of Oncolytic Adenovirus Co-Expressing IL-12 and shVEGF Combined with Anti-PD-1 in Renal Cell Carcinoma

Abstract B053: Neoadjuvant Personalized Viral Vectored vaccines are highly effective against tumor relapse in checkpoint inhibitor resistant murine models

Recombinant Adenovirus Expressing the Fusion Protein PD1PVR Improves CD8+ T Cell-Mediated Antitumor Efficacy with Long-Term Tumor-Specific Immune Surveillance in Hepatocellular Carcinoma

A PD-L1 tropism-expanded oncolytic adenovirus enhanced gene delivery efficiency and anti-tumor effects

Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer

Oncolytic Adenovirus Armed with a Novel Agonist of the CD137 Immune Checkpoint Stimulator Suppresses Tumor Growth

Abstract A058: Oncolytic adenovirus induces potent anti-tumor efficacy via robust activation of immune cells in bladder cancer

CXCL10-armed oncolytic adenovirus promotes tumor-infiltrating T-cell chemotaxis to enhance anti-PD-1 therapy

Combined p14ARF and Interferon-β Gene Transfer to the Human Melanoma Cell Line SK-MEL-147 Promotes Oncolysis and Immune Activation

Efficacy and advantage of immunotherapy for melanoma via intramuscular co-expression of plasmid-encoded PD-1 and CTLA-4 scFvs

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

An oncolytic virus–T cell chimera for cancer immunotherapy

Enhancing the Efficacy of Breast Cancer Immunotherapy Using a Smac-Armed Oncolytic Virus

A New Oncolytic Adenoviral Vector Carrying Dual Tumour Suppressor Genes Shows Potent Anti-Tumour Effect

Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade